METHODS FOR ENHANCING TCRab+ CELL DEPLETION EFFICIENCY
AssigneeAllogene Therapeutics, Inc.
InventorsYajin NI, Hongxiu NING, Janet M. LEE, Mark W. LEONARD
Life of this patent
Estimating the term…
Abstract
Provided herein are improved methods for robust TCR+ cell depletion and production of populations of TCR− cells, which can be beneficial to minimize the GvHD risk in patients receiving allogeneic CAR T cell therapy. Provided herein are methods that increase the efficiency of depleting TCR+ cells from a population of cells in order to significantly reduce any residual levels of TCR+ cells present in cell populations in which expression of endogenous TCR has been reduced or eliminated. Associated kits and cell populations are also provided.
Claims28
1-39. (canceled)
A method of producing a population of immune cells depleted of immune cells expressing an endogenous TCR, the method comprising:
- (a) labeling a population of immune cells with an anti-TCR antibody and an anti-CD3 antibody;
- and
- (b) separating anti-TCR antibody labeled immune cells and anti-CD3 antibody labeled immune cells from the population of immune cells.
A method of depleting cells expressing an endogenous TCR from a population of immune cells comprising:
- (a) labeling the population of immune cells with an anti-TCR antibody and an anti-CD3 antibody;
- (b) separating anti-TCR antibody labeled immune cells and anti-CD3 antibody labeled immune cells from unlabeled immune cells;
- and
- (c) collecting the unlabeled immune cells,
- thereby obtaining a population of immune cells that are depleted of cells expressing an endogenous TCR.
A method of producing a population of immune cells depleted of immune cells expressing an endogenous TCR, the method comprising:
- (c) labeling a population of immune cells with an anti-TCR antibody and an anti-CD52 antibody;
- and
- (d) separating anti-TCR antibody labeled immune cells and anti-CD52 antibody labeled immune cells from the population of immune cells.
A method of depleting cells expressing an endogenous TCR from a population of immune cells comprising:
- (d) labeling the population of immune cells with an anti-TCR antibody and an anti-CD52 antibody;
- (e) separating anti-TCR antibody labeled immune cells and anti-CD52 antibody labeled immune cells from unlabeled immune cells;
- and
- (f) collecting the unlabeled immune cells,
- thereby obtaining a population of immune cells that are depleted of cells expressing an endogenous TCR.
Dependencies are inferred from the claim text.